Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjay Choudhary

Internal Medicine Middleburg Heights, OH Medical Doctor

NPI 1407858228 CMS profile 1114957

7215 Old Oak Blvd, Suite A420, Middleburg Heights, OH 44130

Open in the dashboard

General payments

$11,864

736 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjay Choudhary of Middleburg Heights, OH is reported in the CMS Open Payments database as having received $11,864 across 736 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,510 81
2024 General $1,440 71
2023 General $1,765 104
2022 General $1,874 134
2021 General $2,076 118
2020 General $1,506 113
2019 General $1,693 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjay Choudhary
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sanjay Choudhary were reported at $1,510. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sanjay Choudhary Internal Medicine median Middle half National median
2019 $1,693 $159 $48–$570 $163
2020 $1,506 $119 $33–$402 $114
2021 $2,076 $135 $37–$521 $132
2022 $1,874 $141 $42–$496 $149
2023 $1,765 $149 $45–$519 $160
2024 $1,440 $154 $47–$537 $164
2025 $1,510 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,883 70 payments
  2. AbbVie, Inc. $1,536 111 payments
  3. GlaxoSmithKline, LLC. $740 57 payments
  4. Novo Nordisk Inc $676 50 payments
  5. Allergan Inc. $528 47 payments
  6. Amgen Inc. $498 29 payments
  7. Janssen Pharmaceuticals, Inc $470 28 payments
  8. Otsuka America Pharmaceutical, Inc. $396 23 payments
  9. Novartis Pharmaceuticals Corporation $395 35 payments
  10. Axsome Therapeutics, Inc. $384 19 payments
  11. Other $4,357 267 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,756 733 payments
  2. Education $107 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,145 38 payments
  2. TRELEGY ELLIPTA $670 52 payments
  3. VRAYLAR Neuroscience $626 44 payments
  4. BREZTRI $618 17 payments
  5. Ozempic $484 44 payments
  6. AIRSUPRA $480 12 payments
  7. LOKELMA $467 8 payments
  8. VRAYLAR Neuroscience $403 40 payments
  9. REXULTI $396 23 payments
  10. Auvelity $384 19 payments
  11. Other $8,694 583 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

4,905

Median for Internal Medicine: 777

Drug cost

$528,707

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $71,726
Farxiga Dapagliflozin Propanediol Brand 48 $54,407
Eliquis Apixaban Brand 71 $49,306
Ozempic Semaglutide Brand 27 $42,313
Mounjaro Tirzepatide Brand 25 $31,115
Jardiance Empagliflozin Brand 30 $29,681
Rybelsus Semaglutide Brand 14 $27,171
Rexulti Brexpiprazole Brand 12 $24,232
Kerendia Finerenone Brand 15 $20,389
Januvia Sitagliptin Phosphate Brand 22 $20,052

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$171,967

Of which drugs: $590

Medicare patients

360

Average age 75

Services billed

2,216

189 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 45%
Depression 45%
Heart failure 44%
Chronic kidney disease 43%
Diabetes 42%
Atrial fibrillation 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$182 15 —
BREZTRI
$160 16 —
AIRSUPRA
$141 — —
VRAYLAR
$136 — —
REXULTI
$82 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

736 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record